Phase I Trial Combining Venetoclax with Cladribine, Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) for Patients with Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms

被引：0
|
作者：
Raychaudhuri, Suravi [1 ,2 ]
Gooley, Ted [2 ]
Rasmussen, Allegra [1 ]
Quach, Kim [1 ]
Gill, Zach [1 ]
Halpern, Anna B. [1 ,2 ]
Appelbaum, Jacob S. [2 ,3 ]
Ghiuzeli, Cristina Maria [1 ,2 ]
Hendrie, Paul C. [1 ,2 ]
Cassaday, Ryan D. [1 ,2 ]
Walter, Roland B. [4 ,5 ]
Estey, Elihu [1 ,2 ]
Percival, Mary-Elizabeth M. [3 ,6 ]
机构：
[1] Fred Hutchinson Canc Ctr, Seattle, WA USA
[2] Univ Washington, Seattle, WA USA
[3] Fred Hutchinson Canc Ctr, Clin Res Div, Seattle, WA USA
[4] Fred Hutchinson Canc Ctr, Translat Sci & Therapeut Div, Seattle, WA USA
[5] Univ Washington, Dept Med, Div Hematol & Oncol, Seattle, WA USA
[6] Univ Washington, Div Hematol & Oncol, Sch Med, Seattle, WA USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-200883
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4288 / 4289
页数：2
相关论文
共 50 条
  • [1] Phase I Trial Combining Venetoclax with G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients with High-Grade Myeloid Neoplasms
    Raychaudhuri, Suravi
    Gooley, Ted
    Gill, Zach
    Rasmussen, Allegra
    Halpern, Anna B.
    Appelbaum, Jacob S.
    Ghiuzeli, Cristina Maria
    Hendrie, Paul C.
    Cassaday, Ryan D.
    Walter, Roland B.
    Estey, Elihu
    Percival, Mary-Elizabeth M.
    BLOOD, 2023, 142
  • [2] Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms
    Halpern, Anna B.
    Othus, Megan
    Gardner, Kelda
    Alcorn, Genevieve
    Percival, Mary-Elizabeth M.
    Huebner, Emily M.
    Scott, Bart L.
    Becker, Pamela S.
    Hendrie, Paul C.
    Oehler, Vivian G.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2019, 134
  • [3] Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
    Godwin, Colin D.
    Othus, Megan
    Percival, Mary-Elizabeth M.
    Scott, Bart L.
    Becker, Pamela S.
    Gardner, Kelda M.
    Keel, Sioban B.
    Dhawale, Tejaswini M.
    Oehler, Vivian G.
    Abkowitz, Janis L.
    Halpern, Anna B.
    Hendrie, Paul C.
    Orlowski, Kaysey F.
    Woo, Alice
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2019, 134
  • [4] Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Scott, Bart L.
    Hendrie, Paul C.
    Percival, Mary-Elizabeth M.
    Becker, Pamela S.
    Smith, Heather A.
    Oehler, Vivian G.
    Orozco, Johnnie J.
    Cassaday, Ryan D.
    Gardner, Kelda M.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Anwar, Asma
    Estey, Elihu H.
    Walter, Roland B.
    HAEMATOLOGICA, 2019, 104 (04) : E143 - E146
  • [5] Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with NewlyDiagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
    Halpern, Anna B.
    Rodriguez-Arboli, Eduardo P.
    Othus, Megan
    Garcia, Kelsey-Leigh A.
    Percival, Mary-Elizabeth M.
    Cassaday, Ryan D.
    Oehler, Vivian G.
    Becker, Pamela S.
    Appelbaum, Jacob S.
    Abkowitz, Janis L.
    Orozco, Johnnie J.
    Keel, Sioban B.
    Hendrie, Paul C.
    Scott, Bart L.
    Ghiuzeli, Cristina
    Walter, Roland B.
    Estey, Elihu H.
    BLOOD, 2022, 140 : 8999 - 9001
  • [6] A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
    Godwin, Colin D.
    Othus, Megan
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Scott, Bart L.
    Appelbaum, Jacob S.
    Halpern, Anna B.
    Oehler, Vivian G.
    Orozco, Johnnie J.
    Keel, Sioban B.
    Abkowitz, Janis L.
    Cooper, Jason P.
    Cassaday, Ryan D.
    Orlowski, Kaysey F.
    Marshall, Anise J.
    Brown, Clarisa N.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2021, 138
  • [7] Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm
    Palmieri, Raffaele
    Buckley, Sarah A.
    Othus, Megan
    Halpern, Anna B.
    Percival, Mary-Elizabeth M.
    Scott, Bart L.
    Hendrie, Paul C.
    Becker, Pamela S.
    Oehler, Vivian G.
    Estey, Elihu H.
    Walter, Roland B.
    LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1728 - 1731
  • [8] Invasive fungal infections after CLAG-M/CLAG chemotherapy for acute myeloid leukemia and high-grade myeloid neoplasms
    Lindsay, Julian
    Walti, Carla S.
    Halpern, Anna B.
    Xie, Hu
    Chung, E. Lisa
    Schonhoff, Kelda G.
    Huebner, Emily M.
    Cheng, Guang-Shing
    Kimball, Louise E.
    Leisenring, Wendy M.
    Greenwood, Matthew
    Chen, Sharon C. -A.
    Kong, David C. M.
    Slavin, Monica A.
    Boeckh, Michael
    Fredricks, David N.
    Liu, Catherine
    Pergam, Steven A.
    Walter, Roland B.
    Hill, Joshua A.
    BLOOD ADVANCES, 2023, 7 (13) : 3140 - 3145
  • [9] Outcomes in Patients with Acute Myeloid Leukemia Treated with CLAG (cladribine, cytarabine, filgrastim) and/or Mitoxantrone with Venetoclax
    Chan, Onyee
    Aguirre, Luis E.
    Burke, Mary
    Al Ali, Najla H.
    Xie, Zhuoer
    Yun, Seongseok
    Kuykendall, Andrew T.
    Padron, Eric
    Walker, Alison R.
    Lancet, Jeffrey
    Komrokji, Rami S.
    Sallman, David A.
    BLOOD, 2023, 142
  • [10] G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (GCLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Grade Myeloid Neoplasms: Final Results from a Phase 1/2 Trial
    Halpern, Anna B.
    Huebner, Emily M.
    Othus, Megan
    Scott, Bart L.
    Becker, Pamela S.
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Gardner, Kelda M.
    Buckley, Sarah A.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2017, 130
12345